

Date: 05<sup>th</sup> November, 2025

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
Scrip Code: 533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APLLTD

Dear Sir/Madam,

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Publication of Unaudited Financial Results**

With reference to the captioned subject, we enclose herewith Newspaper cuttings of extract of Unaudited Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2025, published in Economic Times & Indian Express (English Edition) and Financial Express (Gujarati Edition) on 05<sup>th</sup> November, 2025.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

**For Alembic Pharmaceuticals Limited**

  
**Manisha Saraf**  
Company Secretary



Encl.: A/a.

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880  
Website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN: L24230GJ2010PLC061123



**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of statement of Consolidated Unaudited Financial Results  
for the quarter ended 30<sup>th</sup> September, 2025****(₹ in Crores except per share data)**

| Particulars                                                                                                                     | Quarter Ended             |                           | Year Ended              |
|---------------------------------------------------------------------------------------------------------------------------------|---------------------------|---------------------------|-------------------------|
|                                                                                                                                 | 30.09.2025<br>(Unaudited) | 30.09.2024<br>(Unaudited) | 31.03.2025<br>(Audited) |
| Total Income from Operations                                                                                                    | <b>1,910.15</b>           | 1,647.98                  | 6,672.08                |
| Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)                                                 | <b>223.72</b>             | 167.55                    | 694.31                  |
| Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)                                            | <b>223.72</b>             | 180.42                    | 707.18                  |
| Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items) | <b>184.71</b>             | 153.41                    | 583.42                  |
| Total Comprehensive Income for the period                                                                                       | <b>188.38</b>             | 154.45                    | 587.54                  |
| Equity Share Capital                                                                                                            | <b>39.31</b>              | 39.31                     | 39.31                   |
| Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year                                 | —                         | —                         | 5,151.63                |
| Earning Per Share (Face Value of ₹2/- each) Basic & Diluted                                                                     | <b>9.40</b>               | 7.79                      | 29.68                   |

**Notes:**

| 1. Standalone details  | Quarter Ended             |                           | Year Ended              |
|------------------------|---------------------------|---------------------------|-------------------------|
|                        | 30.09.2025<br>(Unaudited) | 30.09.2024<br>(Unaudited) | 31.03.2025<br>(Audited) |
| Income from Operations | <b>1,796.24</b>           | 1,580.35                  | 6,032.63                |
| Profit Before Tax      | <b>216.35</b>             | 187.15                    | 595.72                  |
| Profit After Tax       | <b>179.36</b>             | 165.78                    | 503.12                  |

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.

**For Alembic Pharmaceuticals Limited**

Sd/-

**Chirayu Amin****Chairman and CEO**

Place : Mumbai

Date : 4<sup>th</sup> November, 2025



**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of statement of Consolidated Unaudited Financial Results  
for the quarter ended 30<sup>th</sup> September, 2025**

(₹ in Crores except per share data)

| Particulars                                                                                                                     | Quarter Ended             |                           | Year Ended              |
|---------------------------------------------------------------------------------------------------------------------------------|---------------------------|---------------------------|-------------------------|
|                                                                                                                                 | 30.09.2025<br>(Unaudited) | 30.09.2024<br>(Unaudited) | 31.03.2025<br>(Audited) |
| Total Income from Operations                                                                                                    | 1,910.15                  | 1,647.98                  | 6,672.08                |
| Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)                                                 | 223.72                    | 167.55                    | 694.31                  |
| Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)                                            | 223.72                    | 180.42                    | 707.18                  |
| Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items) | 184.71                    | 153.41                    | 583.42                  |
| Total Comprehensive Income for the period                                                                                       | 188.38                    | 154.45                    | 587.54                  |
| Equity Share Capital                                                                                                            | 39.31                     | 39.31                     | 39.31                   |
| Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year                                 | —                         | —                         | 5,151.63                |
| Earning Per Share (Face Value of ₹2/- each) Basic & Diluted                                                                     | 9.40                      | 7.79                      | 29.68                   |

**Notes:**

| 1. Standalone details  | Quarter Ended             |                           | Year Ended              |
|------------------------|---------------------------|---------------------------|-------------------------|
|                        | 30.09.2025<br>(Unaudited) | 30.09.2024<br>(Unaudited) | 31.03.2025<br>(Audited) |
| Income from Operations | 1,796.24                  | 1,580.35                  | 6,032.63                |
| Profit Before Tax      | 216.35                    | 187.15                    | 595.72                  |
| Profit After Tax       | 179.36                    | 165.78                    | 503.12                  |

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.



For Alembic Pharmaceuticals Limited

Sd/-

Place : Mumbai

Date : 4<sup>th</sup> November, 2025
**Chiray Amin**  
Chairman and CEO

Vadodara





## ALEMBIC PHARMACEUTICALS LIMITED

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: [apl.investors@alembic.co.in](mailto:apl.investors@alembic.co.in)

Website: [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com)

### Extract of statement of Consolidated Unaudited Financial Results for the quarter ended 30<sup>th</sup> September, 2025

(₹ in Crores except per share data)

| Particulars                                                                                                                     | Quarter Ended             |                           | Year Ended              |
|---------------------------------------------------------------------------------------------------------------------------------|---------------------------|---------------------------|-------------------------|
|                                                                                                                                 | 30.09.2025<br>(Unaudited) | 30.09.2024<br>(Unaudited) | 31.03.2025<br>(Audited) |
| Total Income from Operations                                                                                                    | 1,910.15                  | 1,647.98                  | 6,672.08                |
| Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)                                                 | 223.72                    | 167.55                    | 694.31                  |
| Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)                                            | 223.72                    | 180.42                    | 707.18                  |
| Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items) | 184.71                    | 153.41                    | 583.42                  |
| Total Comprehensive Income for the period                                                                                       | 188.38                    | 154.45                    | 587.54                  |
| Equity Share Capital                                                                                                            | 39.31                     | 39.31                     | 39.31                   |
| Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year                                 | —                         | —                         | 5,151.63                |
| Earning Per Share (Face Value of ₹2/- each) Basic & Diluted                                                                     | 9.40                      | 7.79                      | 29.68                   |

#### Notes:

| 1. Standalone details  | Quarter Ended             |                           | Year Ended              |
|------------------------|---------------------------|---------------------------|-------------------------|
|                        | 30.09.2025<br>(Unaudited) | 30.09.2024<br>(Unaudited) | 31.03.2025<br>(Audited) |
| Income from Operations | 1,796.24                  | 1,580.35                  | 6,032.63                |
| Profit Before Tax      | 216.35                    | 187.15                    | 595.72                  |
| Profit After Tax       | 179.36                    | 165.78                    | 503.12                  |

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.



For Alembic Pharmaceuticals Limited

Sd/-

Chirayu Amin

Chairman and CEO

Place : Mumbai

Date : 4<sup>th</sup> November, 2025